What we state must remain verifiable.

Medical governance and independent specialist review of aesthetic-medicine decisions.

Constitutional purpose, defined mandate scope and a binding separation from clinical care.

UHNW Aesthetics provides no treatment, receives no referral fees or commissions and holds no direct or indirect financial interest in any clinic or practitioner under review.

Binding declarations, case-specific conflict-of-interest review and documented separation of roles.

The legal entity, authority to represent it, registered office, register details and basis of its non-profit status must be unambiguously identifiable.

Incorporation and register records, proof of authority to represent, status documentation and the current matrix of responsibilities.

An accepted and operationally approved mandate scope may be translated into verifiable deliverables. The accepted scope and operational status determine which formats are actually available.

Evidence record, red-flag analysis, decision brief, outstanding review questions, conditions and escalation pathway.

The number of reviewers, reasons for their selection, review timeframe, reporting format and escalation pathway are disclosed before a mandate is accepted.

A case-specific review plan defining roles, information boundaries, milestones and named accountability.

Competence is assessed against primary registers and documented criteria; public prominence is not evidence of competence.

Professional and licensing registers, documented clinical practice, scientific responsibility and robust data on the facility, team and outcomes. PHIN may serve as one source in the UK private healthcare sector; no affiliation is claimed.

Phase 1 is an institutional, non-individual layer built on an owner-confirmed inventory of more than 3,000 general review criteria; individual criteria remain protected and require validation plus scope-specific authorisation. Phase 2 does not add those criteria to a case total. Under a new direct mandate, the reviewing physician may activate more than 3,000 and, where the physician-approved case ledger supports it, up to 10,000 materially independent case-specific review points. The exact count is a ledger result, not a package size or forecast.

The protected, version-controlled register records counting rule, deduplication, provenance, activation, medical approval, responsible physician and change history across indication, physician, team, facility, anaesthesia, product, aftercare, revision, travel and long-term strategy. Phase 1 criteria and Phase 2 review points are not added together. Controlled extension requires new evidence, a new version and physician approval. Phase 2 case data remain in the directly mandated physician’s protected professional system; UHNW neither treats nor receives the medical Phase 2 fee.

Identity, the preliminary access review, the medical case file and specialist access remain separate information layers.

Data controller, legal basis, retention periods, categories of recipients, access logs and documented routes for rectification and erasure.

UHNW Aesthetics does not rely on public uniqueness, market-leadership or comparative-safety claims. The public case for a mandate is made through defined scope, roles, evidence, deliverables and operating boundaries.

Any future comparative claim would require a version-controlled market review with defined terms, search scope, cut-off date, comparison matrix, primary-source archive, documented exclusions, accountable review, challenge procedure and periodic reassessment before publication.